Polymorphic light eruption
| Autor: | William D Tutrone, Candace Thornton Spann, Noah Scheinfeld, Vincent A. DeLeo |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Niacinamide
medicine.medical_specialty Sun protection medicine.medical_treatment Photodermatosis Comorbidity Dermatology medicine Humans Lupus Erythematosus Systemic Polymorphic light eruption Photosensitivity Disorders PUVA Therapy Arachidonic Acid Lupus erythematosus integumentary system business.industry Erythematous papule General Medicine medicine.disease Arachidonic acid metabolism Hypersensitivity reaction Treatment Outcome PUVA therapy Dermatologic Agents business Sunscreening Agents Hydroxychloroquine |
| Zdroj: | Dermatologic Therapy. 16:28-39 |
| ISSN: | 1529-8019 1396-0296 |
| DOI: | 10.1046/j.1529-8019.2003.01605.x |
| Popis: | Polymorphic light eruption (PMLE) is the most common photodermatosis. It is typically characterized by nonscarring, pruritic, erythematous papules, plaques, or vesicles on sun-exposed skin that develop 30 minutes to several hours after sun exposure. The eruption may persist for a few hours to as long as 2 weeks. Females are affected two to three times more often than males. PMLE has been reported in all races, but tends to affect fair-skinned individuals with Fitzpatrick skin types I-IV most commonly. The pathogenesis of PMLE has been difficult to define, although it appears to be an immune-mediated delayed-type hypersensitivity reaction. Abnormalities of arachidonic acid metabolism and a possible correlation with lupus are other theories that are reviewed. Treatment options have been explored extensively. While "hardening" or desensitization of the skin through repeated irradiation seems to be the most effective, therapeutic options such as sun avoidance/sun protection, oral carotenoids, and antimalarials are also considered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|